Your browser doesn't support javascript.
Good practice statements for antithrombotic therapy in the management of COVID-19: Guidance from the SSC of the ISTH.
Spyropoulos, Alex C; Connors, Jean M; Douketis, James D; Goldin, Mark; Hunt, Beverley J; Kotila, Taiwo R; Lopes, Renato D; Schulman, Sam.
  • Spyropoulos AC; Institute of Health Systems Science-Feinstein Institutes for Medical Research, Manhasset, New York, USA.
  • Connors JM; The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hemptead, New York, USA.
  • Douketis JD; Department of Medicine, Anticoagulation and Clinical Thrombosis Services, Northwell Health at Lenox Hill Hospital, New York, New York, USA.
  • Goldin M; Hematology Division Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Hunt BJ; Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
  • Kotila TR; Institute of Health Systems Science-Feinstein Institutes for Medical Research, Manhasset, New York, USA.
  • Lopes RD; The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hemptead, New York, USA.
  • Schulman S; Thrombosis & Haemophilia Centre, Guy's & St Thomas' NHS Foundation Trust, London, UK.
J Thromb Haemost ; 20(10): 2226-2236, 2022 10.
Article in English | MEDLINE | ID: covidwho-1916260
ABSTRACT
Despite the emergence of high quality randomized trial data with the use of antithrombotic agents to reduce the risk of thromboembolism, end-organ failure, and possibly mortality in patients with coronavirus disease 2019 (COVID-19), questions still remain as to optimal patient selection for these strategies, the use of antithrombotics in outpatient settings and in-hospital settings (including critical care units), thromboprophylaxis in special patient populations, and the management of acute thrombosis in hospitalized COVID-19 patients. In October 2021, the International Society on Thrombosis and Haemostasis (ISTH) formed a multidisciplinary and international panel of content experts, two patient representatives, and a methodologist to develop recommendations on treatment with anticoagulants and antiplatelet agents for COVID-19 patients. The ISTH Guideline panel discussed additional topics to be well suited to a non-Grading of Recommendations Assessment, Development, and Evaluation (GRADE) for Good Practice Statements (GPS) to support good clinical care in the antithrombotic management of COVID-19 patients in various clinical settings. The GPS panel agreed on 17 GPS 3 in the outpatient (pre-hospital) setting, 12 in the hospital setting both in non-critical care (ward) as well as intensive care unit settings, and 2 in the immediate post-hospital discharge setting based on limited evidence or expert opinion that supports net clinical benefit in enacting the statements provided. The antithrombotic therapies discussed in these GPS should be available in low- and middle-income countries.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Fibrinolytic Agents / COVID-19 Drug Treatment Type of study: Experimental Studies / Prognostic study / Randomized controlled trials Topics: Long Covid Limits: Humans Language: English Journal: J Thromb Haemost Journal subject: Hematology Year: 2022 Document Type: Article Affiliation country: Jth.15809

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Fibrinolytic Agents / COVID-19 Drug Treatment Type of study: Experimental Studies / Prognostic study / Randomized controlled trials Topics: Long Covid Limits: Humans Language: English Journal: J Thromb Haemost Journal subject: Hematology Year: 2022 Document Type: Article Affiliation country: Jth.15809